Health Canada Medical Device License: The Complete Guide

How to obtain a Medical Device License from Health Canada — classification, MDSAP requirements, MDEL, application process, fees, and practical guidance for the Canadian market.

Why the Canadian Market Matters

Canada is one of the world's most important medical device markets. With a universal publicly funded healthcare system, a population of approximately 40 million, and healthcare spending exceeding CAD 330 billion annually, the demand for medical technology is substantial and growing. Canada consistently ranks among the top ten global medical device markets by revenue.

But market size alone does not explain why Canada deserves dedicated regulatory attention. Three factors make the Canadian market strategically significant for device manufacturers:

Regulatory credibility. A Health Canada Medical Device License (MDL) carries significant weight internationally. Health Canada is a founding member of the International Medical Device Regulators Forum (IMDRF) and has been at the forefront of regulatory harmonization through programs like MDSAP. A Canadian license signals regulatory maturity to other markets.
MDSAP gateway. Canada was the first country to make the Medical Device Single Audit Program (MDSAP) mandatory. If you are already pursuing MDSAP certification for other markets (US, Australia, Brazil, Japan), adding Canada to your MDSAP scope is incremental — and you cannot sell Class II–IV devices in Canada without it.
Alignment with global standards. Canada's regulatory requirements are built on ISO 13485, use risk-based classification similar to the EU and GHTF models, and recognize clinical evidence generated under international standards. For manufacturers already selling in the US or EU, the Canadian pathway is often more accessible than it first appears.

This guide covers the entire landscape: the regulatory framework, device classification, establishment licensing, the Medical Device License application process, MDSAP requirements, clinical evidence expectations, labeling, fees, timelines, post-market obligations, and practical tips for foreign manufacturers entering the Canadian market.

The Canadian Regulatory Framework

Governing Legislation

Medical devices in Canada are regulated under two primary pieces of legislation:

The Food and Drugs Act (FDA) — the overarching statute that gives the federal government authority to regulate food, drugs, cosmetics, and medical devices. (Note: Canada's Food and Drugs Act shares the same abbreviation as the US agency, which can cause confusion. In this guide, "FDA" refers to Canada's Food and Drugs Act only when explicitly stated; otherwise, references to FDA mean the US Food and Drug Administration.)
The Medical Devices Regulations (SOR/98-282) — the detailed regulations under the Food and Drugs Act that establish the classification system, licensing requirements, labeling rules, quality system obligations, and post-market requirements for medical devices in Canada.

Health Canada's Therapeutic Products Directorate (TPD) and Medical Devices Bureau (MDB) within the Health Products and Food Branch (HPFB) are responsible for the pre-market review and post-market oversight of medical devices.

What Qualifies as a Medical Device in Canada?

Under the Food and Drugs Act, a medical device is any instrument, apparatus, contrivance, or article — including any component, part, or accessory — that is manufactured, sold, or represented for use in:

Diagnosing, treating, mitigating, or preventing a disease, disorder, or abnormal physical state (or its symptoms) in human beings
Restoring, correcting, or modifying a body function or body structure in human beings
Diagnosing pregnancy in human beings
Care of human beings during pregnancy and at or after birth, including care of the infant
In vitro diagnostics

Software that meets this definition is regulated as a medical device — including Software as a Medical Device (SaMD).

Two Licenses You Need: MDEL and MDL

Foreign manufacturers often confuse these two requirements. They are distinct and both are mandatory:

License	Full Name	What It Covers	Who Needs It
MDEL	Medical Device Establishment License	Authorization for an establishment (company) to import, distribute, or sell medical devices in Canada	Any company that imports, distributes, or sells devices in Canada — including foreign manufacturers who sell directly
MDL	Medical Device License	Authorization for a specific medical device (or device family) to be sold in Canada	Required for all Class II, III, and IV devices. Class I devices do not require an MDL.

Think of the MDEL as the company license and the MDL as the product license. You need both (except for Class I devices, which require only an MDEL, not an MDL).

Device Classification: Classes I Through IV

Canada uses a four-class risk-based classification system. The system is derived from the Global Harmonization Task Force (GHTF) model and shares conceptual similarities with both the EU and Australian classification approaches — but the specific rules and class boundaries differ.

Classification Overview

Class	Risk Level	Examples	MDL Required?	MDSAP Required?
Class I	Lowest	Tongue depressors, elastic bandages, non-powered surgical instruments, reusable scalpel handles	No	No
Class II	Low-moderate	Contact lenses, pregnancy test kits, powered wheelchairs, blood collection tubes, surgical gloves, condoms	Yes	Yes
Class III	Moderate-high	Orthopedic implants (screws, plates), hemodialysis equipment, glucose monitors, ventilators, surgical lasers	Yes	Yes
Class IV	Highest	Cardiac pacemakers, drug-eluting stents, total hip replacement systems, defibrillators, heart valves, absorbable sutures with antimicrobials	Yes	Yes

Classification Rules

The Medical Devices Regulations contain classification rules in Schedule 1 that assign devices to classes based on:

Intended use and invasiveness — whether the device is invasive, how long it contacts the body, whether it contacts the cardiovascular or central nervous system
Energy source — whether the device is active (powered by an energy source other than gravity or the human body)
Whether the device is an IVD — in vitro diagnostic devices have separate classification rules
Whether it contains or is used with a drug, biological material, or animal/human tissue

The classification rules work by assigning a device to the highest applicable class when multiple rules apply. Key classification principles:

Rule 1 (Invasive devices): Devices that penetrate the body through a body orifice or through the body surface are classified based on duration of contact and the part of the body contacted. Contact with the cardiovascular system or central nervous system drives classification higher.

Rule 2 (Active devices): Active devices intended for diagnosis are generally Class II. Active therapeutic devices intended to deliver or exchange energy are Class II unless they are intended to deliver energy to the body in a potentially hazardous way (Class III or IV depending on the nature of the energy and the risk).

Rule 3 (IVD devices): IVDs are classified from Class I to Class IV based on the risk associated with an incorrect result. IVDs for blood grouping, HIV/HCV/HBV screening, and other high-risk infectious disease markers are Class IV. IVDs for self-testing are generally higher classification than the equivalent lab-use device.

Rule 4 (Devices that are part of a system): Devices intended to be used in combination with other devices are classified according to the intended use of the combined system.

Rule 5 (Special devices): Devices manufactured from or incorporating animal or human tissue, devices containing drugs, and devices intended to administer drugs are classified according to specific rules that generally push them into Class III or IV.

Practical tip: Classification determines everything downstream — the type of license application, the depth of review, the evidence requirements, MDSAP scope, and fees. If you are uncertain about your device's classification, request a classification determination from Health Canada before starting the licensing process. The request is informal and can save months of wasted effort if you get the classification wrong. Health Canada's Medical Devices Bureau can provide written classification opinions.

Canada vs. FDA vs. EU Classification Comparison

Understanding how your device's classification maps across jurisdictions is essential for planning multi-market submissions.

Device Example	Canada	FDA (US)	EU MDR
Tongue depressor	Class I	Class I (exempt)	Class I
Surgical gloves	Class II	Class I (exempt)	Class I
Pregnancy test (self-test)	Class II	Class II (510(k))	Class C (IVDR)
Contact lens (daily wear)	Class II	Class II (510(k))	Class IIa
Powered wheelchair	Class II	Class II (510(k))	Class I
Glucose monitor	Class III	Class II (510(k))	Class IIb
Orthopedic hip screw	Class III	Class II (510(k))	Class IIb
Ventilator	Class III	Class II (510(k))	Class IIb
Cardiac pacemaker	Class IV	Class III (PMA)	Class III
Drug-eluting coronary stent	Class IV	Class III (PMA)	Class III
Defibrillator (ICD)	Class IV	Class III (PMA)	Class III

Note: Canadian classification can differ from what manufacturers expect based on their US or EU experience. A device that is Class II (510(k)) in the US may be Class III in Canada, which triggers a more demanding review process. Always classify independently for Canada rather than assuming alignment.

Medical Device Establishment License (MDEL)

Before you can sell any medical device in Canada — regardless of class — your company must hold a Medical Device Establishment License (MDEL).

Who Needs an MDEL?

An MDEL is required for any person or company that:

Imports medical devices into Canada
Distributes medical devices in Canada
Sells medical devices in Canada (including online sales to Canadian customers)

Manufacturers located in Canada also need an MDEL if they sell devices. Foreign manufacturers who sell through a Canadian importer or distributor do not need their own MDEL — the importer/distributor must hold one. However, if you sell directly to Canadian customers (even from outside Canada), you need an MDEL.

Who Does NOT Need an MDEL?

Manufacturers who only manufacture and export devices (and do not sell domestically)
Healthcare facilities that use devices in patient care
Retailers who sell only Class I or Class II devices that are already licensed
Companies that only distribute devices under contract for an MDEL holder (in certain circumstances)

MDEL Application Requirements

The MDEL application requires:

Company information — legal name, physical address, contact details
List of device activities — importation, distribution, sale (specify which)
Device class and type information — which classes of devices you handle
Quality management system documentation — evidence of procedures covering distribution records, complaint handling, recall procedures, and adverse event reporting. (Note: the QMS requirements for an MDEL holder are less extensive than for a manufacturer — you do not need full ISO 13485 for distribution-only activities, but you do need documented procedures for the activities listed above.)
Canadian representative information (if the applicant is located outside Canada)
Annual fee payment

MDEL Fees

Activity	Annual Fee (CAD)
MDEL — single class of devices	$7,308
MDEL — multiple classes of devices	$8,658

Fees are updated annually. MDEL holders must renew their license every year and continue to meet the applicable requirements. Failure to renew results in the license lapsing, which means you can no longer legally sell or distribute devices in Canada.

MDEL Conditions

MDEL holders must:

Maintain distribution records that allow complete traceability of devices
Have written procedures for complaint handling and adverse event reporting
Have written recall procedures and be able to execute a recall within an appropriate timeframe
Report mandatory adverse events to Health Canada as required
Allow Health Canada inspectors access to their facilities and records
Notify Health Canada of changes to the information on the MDEL (address, activities, etc.)

Medical Device License (MDL) Application Process

The MDL is the product-level authorization required for all Class II, III, and IV medical devices sold in Canada. Class I devices are exempt from MDL requirements but must still meet labeling requirements and be handled by an MDEL-holding establishment.

MDL Application Overview by Class

Requirement	Class II	Class III	Class IV
Application type	Declaration of conformity	Detailed submission	Detailed submission
Review depth	Administrative review + spot checks	In-depth technical review	Comprehensive technical and clinical review
MDSAP certificate	Required	Required	Required
Safety and effectiveness data	Summary-level	Detailed evidence	Extensive clinical and pre-clinical evidence
Clinical evidence	Not typically required for most Class II devices	Often required	Almost always required
Quality system evidence	MDSAP certificate	MDSAP certificate + process validation summaries	MDSAP certificate + detailed QMS evidence
Review timeline	15 calendar days (target)	60–75 calendar days (target)	75 calendar days (target)
License fee (2026)	$643	$14,163	$30,713

What the MDL Application Must Include

Regardless of device class, every MDL application submitted through Health Canada's online system must include:

Device information — device name, identifier, class, intended use, description of the device and how it works, materials of construction
Manufacturer information — legal name, address, MDEL number (or importer's MDEL number)
MDSAP certificate — a valid certificate with Canada in scope, issued by a recognized Auditing Organization
Device labeling — copies of all labels, instructions for use (IFU), and packaging materials in both English and French (bilingual requirements apply)
Declaration of conformity — a signed declaration by the manufacturer that the device meets the safety and effectiveness requirements of the Medical Devices Regulations
Safety and effectiveness summary or evidence — the depth varies by class (see below)
Risk analysis summary — demonstration that risks have been identified, evaluated, and controlled (ISO 14971 is the expected standard)
Fee payment

Class II Applications: Declaration-Based

Class II MDL applications are primarily declaration-based. The manufacturer declares that the device meets the requirements of the Medical Devices Regulations. Health Canada performs an administrative review to verify completeness and may conduct spot checks on specific sections, but does not perform a detailed technical review of every submission.

This does not mean Class II applications are trivial. The manufacturer is legally responsible for the accuracy of the declaration, and Health Canada can audit and request supporting evidence at any time. Incomplete or inaccurate declarations can result in license suspension or refusal.

Key documents for Class II:

Completed application form
MDSAP certificate (Canada in scope)
Bilingual labeling (English and French)
Summary of safety and effectiveness information
Declaration of conformity
Risk analysis summary

Class III Applications: Detailed Review

Class III devices undergo substantive technical review. Health Canada reviewers examine:

Device description and principles of operation in detail
Pre-clinical testing data (bench testing, animal studies if applicable)
Biocompatibility data (per ISO 10993 series) for devices with body contact
Electrical safety and EMC data for powered devices (IEC 60601 series)
Software documentation for devices containing software (IEC 62304, IEC 62366)
Sterilization validation for sterile devices (ISO 11135, ISO 11137, ISO 17665 as applicable)
Clinical evidence — often required, especially for novel devices or devices with significant clinical claims
Risk management file summary (ISO 14971)
Labeling review (bilingual compliance)

Reviewers may issue screening deficiency letters requesting additional information. Each deficiency cycle adds to the review timeline, so submitting a thorough initial application is critical.

Class IV Applications: Comprehensive Review

Class IV devices receive the most rigorous review. Health Canada treats these applications similarly to how the FDA treats PMA submissions — every aspect of safety and effectiveness is scrutinized. Expect:

Everything required for Class III, plus:
Detailed clinical evidence from clinical investigations (or a robust justification for reliance on clinical literature)
Long-term performance data for implantable devices
Post-market surveillance plans
Benefit-risk analysis
Detailed manufacturing process information and validation summaries

Class IV reviews often involve multiple rounds of questions. The initial review target of 75–90 days is the time Health Canada takes to perform its first-pass review — the total elapsed time from submission to license issuance is typically longer when deficiency responses are factored in.

The Application Process Step by Step

Step 1 — Classify your device. Use the classification rules in Schedule 1 of the Medical Devices Regulations. If uncertain, consult Health Canada.

Step 2 — Obtain MDSAP certification. Before you can apply for an MDL for Class II–IV devices, you must have a valid MDSAP certificate with Canada included in the scope. This means selecting a recognized Auditing Organization, scheduling the audit, passing the audit, and receiving the certificate. Allow 6–12 months for this process if you are starting from scratch.

Step 3 — Prepare bilingual labeling. All labeling — device labels, IFU, packaging — must be in both English and French. This is a legal requirement, not a recommendation. Health Canada will refuse applications with English-only labeling.

Step 4 — Compile the technical submission. Assemble all required documentation according to the class-specific requirements. Health Canada provides detailed guidance documents for each device class.

Step 5 — Ensure your MDEL is in place. Either you (if you are the importer/distributor) or your Canadian partner must hold a valid MDEL.

Step 6 — Submit the application. As of February 2, 2026, all MDL applications must be submitted electronically through Health Canada's Regulatory Enrolment Process (REP) and the Common Electronic Submissions Gateway (CESG). Email-based submissions are no longer accepted. Manufacturers must register in the REP system before submitting through CESG. Submissions must follow Health Canada's IMDRF Table of Contents (ToC) structure, including standardized folder naming conventions and document organization — applications that do not follow the required structure may be refused at administrative screening.

Step 7 — Administrative screening and deficiency responses. Health Canada performs an administrative screening of all submissions upon receipt. Under the updated 2026 guidance, if administrative gaps are identified (missing documents, incorrect formatting, incomplete forms), Health Canada issues a request for outstanding information with a 10-day response deadline. Failure to respond within 10 days results in a rejection letter, and no fee is charged. If the submission passes administrative screening but Health Canada's scientific reviewers identify technical gaps or questions during substantive review, you will receive a screening deficiency letter. Respond thoroughly and promptly. For Class III and IV devices, one to three rounds of questions are common.

Step 8 — Receive the MDL. Once Health Canada is satisfied that the device meets all requirements, the MDL is issued. The license number is entered into the Medical Devices Active License Listing (MDALL) database, which is publicly searchable.

MDSAP: The Mandatory Requirement for Canada

What MDSAP Means for Canada

Canada was the first — and as of 2026, the only — MDSAP participating country to make MDSAP certification fully mandatory. Since January 1, 2019, manufacturers of Class II, III, and IV medical devices must hold a valid MDSAP certificate with Canada included in the scope in order to obtain or maintain a Medical Device License.

This replaced the Canadian Medical Device Conformity Assessment System (CMDCAS), which had served as Canada's third-party QMS audit program since 1998.

CMDCAS History

Understanding CMDCAS helps explain how Canada arrived at MDSAP:

Period	Program	How It Worked
Before 1998	No formal third-party QMS audit requirement	Manufacturers self-declared ISO 13485 compliance; Health Canada conducted occasional inspections
1998–2018	CMDCAS	Recognized registrars audited manufacturers against ISO 13485 plus Canadian regulatory requirements. A CMDCAS certificate was required for Class II–IV MDL applications.
2014–2018	MDSAP pilot / transition	MDSAP launched as a pilot alongside CMDCAS. Manufacturers could choose either program. Health Canada signaled that MDSAP would become mandatory.
January 1, 2019 – present	MDSAP mandatory	CMDCAS fully replaced. Only MDSAP certificates are accepted for Class II–IV MDL applications.

MDSAP Audit Requirements Specific to Canada

When an MDSAP audit includes Canada in scope, the Auditing Organization evaluates your quality management system against:

ISO 13485:2016 — the foundation QMS standard
Canadian Medical Devices Regulations (SOR/98-282) — regulatory requirements specific to Canada, including:
- Mandatory problem reporting (adverse event reporting)
- Recall procedures and execution capability
- Distribution records and traceability
- Labeling requirements (bilingual English/French)
- Post-market requirements
- Design control and risk management

The MDSAP audit tasks for Canada are defined in the MDSAP Companion Document for the regulatory requirements of Health Canada. Auditors use this document to ensure all Canada-specific requirements are covered during the audit.

Recognized MDSAP Auditing Organizations

As of 2026, Health Canada recognizes 15 Auditing Organizations authorized to conduct MDSAP audits. Manufacturers must select one of these recognized AOs for their certification:

Auditing Organization	Headquarters
BSI America, Inc.	Herndon, VA, USA
DEKRA Certification B.V.	Arnhem, Netherlands
DNV MEDCERT GmbH	Hamburg, Germany
DNV Product Assurance AS	Hovik, Norway
DQS Med GmbH	Frankfurt, Germany
G-MED (LNE/GMED)	Paris, France
IMQ S.p.A	Milan, Italy
Intertek Testing Services NA Inc.	Kentwood, MI, USA
NSAI (National Standards Authority of Ireland)	Dublin, Ireland
NCC Certificações do Brasil Ltda.	Campinas, Brazil
SGS United Kingdom Ltd.	Ellesmere Port, UK
TUV USA, Inc.	Salem, NH, USA
TUV Rheinland of North America, Inc.	Boxborough, MA, USA
TÜV SÜD America Inc.	Wakefield, MA, USA
UL Solutions	Northbrook, IL, USA

Practical tip: Not all Auditing Organizations have the same availability, geographic coverage, or pricing. Some AOs specialize in certain device types or have stronger presence in specific regions. When selecting an AO, consider their experience with your device type, their availability for scheduling audits on your timeline, and whether they already audit other sites in your corporate group. Switching AOs mid-cycle is possible but adds administrative complexity and potential delays.

MDSAP Audit Cycle and Duration

MDSAP follows a three-year certification cycle based on ISO/IEC 17021:

Audit Phase	Timing	Purpose
Stage 1 (Initial)	Year 0	Document review, QMS readiness assessment, planning for Stage 2
Stage 2 (Initial)	Year 0 (after Stage 1)	Full on-site QMS audit against ISO 13485 and applicable regulatory requirements
Surveillance 1	Year 1	Annual on-site audit covering a subset of QMS processes
Surveillance 2	Year 2	Annual on-site audit covering remaining QMS processes
Recertification	Year 3	Comprehensive re-audit of the full QMS; new three-year cycle begins

The number of audit days depends on the number of regulatory jurisdictions in scope, the number of manufacturing sites, the number of employees involved in QMS activities, and the complexity of the device portfolio. For a single-site manufacturer with Canada as the only MDSAP jurisdiction, a typical Stage 2 audit requires 3–5 days on-site. Adding Canada to an existing MDSAP scope that already covers the US typically adds 1–2 additional audit days per cycle.

What Happens If Your MDSAP Certificate Lapses

If your MDSAP certificate expires, is suspended, or is withdrawn:

Health Canada will not issue new MDLs for your devices
Existing MDLs may be suspended or cancelled
You cannot legally sell Class II–IV devices in Canada until the certificate is restored
There is no grace period — the requirement is continuous

This is one of the most consequential aspects of the Canadian regulatory system. Your MDSAP certificate is not a one-time checkbox; it is a continuously maintained prerequisite for market access.

MDSAP vs. Other Countries: Why Canada Is Unique

While five countries participate in MDSAP (Canada, the United States, Australia, Brazil, and Japan), each treats MDSAP differently:

Country	MDSAP Status	Implications
Canada	Mandatory (since January 1, 2019)	No MDSAP certificate with Canada in scope = no MDL for Class II–IV devices. No exceptions.
United States	Voluntary (recognized alternative to FDA inspection)	MDSAP can substitute for routine FDA facility inspections, but manufacturers can still be inspected directly by FDA. Not required for 510(k)/PMA clearance.
Australia	Recognized (accepted for TGA conformity assessment)	MDSAP can be used as evidence of QMS compliance for TGA registration, but is not the only pathway.
Brazil	Recognized (ANVISA accepts MDSAP)	MDSAP certificates are accepted for ANVISA medical device registration, reducing the need for ANVISA-specific audits.
Japan	Recognized (PMDA/MHLW accept MDSAP)	MDSAP is accepted as evidence of QMS compliance for certain device registrations in Japan.

Canada's position as the only country where MDSAP is fully mandatory means that the MDSAP certificate is not just a useful efficiency tool — it is the gatekeeper to the Canadian market. This distinction catches many manufacturers off guard, particularly those accustomed to the US system where MDSAP participation is voluntary.

Practical tip: Monitor your MDSAP certificate renewal timeline carefully. Schedule your surveillance audit well in advance — if the audit is delayed and your certificate lapses even briefly, your Canadian MDLs are at risk. Some companies have learned this lesson the hard way when audit scheduling conflicts caused temporary certificate gaps.

Quality Management System Requirements

ISO 13485 as the Foundation

Health Canada expects medical device manufacturers to maintain a quality management system that conforms to ISO 13485:2016. This is verified through the MDSAP audit. The QMS must cover the full product lifecycle:

Management responsibility and resource management
Design and development controls
Purchasing and supplier management
Production and service controls (including process validation)
Monitoring, measurement, analysis, and improvement (CAPA, complaints, internal audits)
Document and record control

Canada-Specific QMS Additions

Beyond ISO 13485, Canada requires specific elements in the QMS:

Mandatory problem reporting procedures — documented procedures for identifying, investigating, and reporting adverse events (mandatory problem reports) to Health Canada within required timeframes
Recall procedures — documented procedures for initiating, executing, and reporting recalls, with the ability to reach all affected customers
Distribution records — sufficient records to identify every device that has been distributed in Canada and to whom, enabling effective recall execution
Bilingual labeling control — procedures to ensure all labeling for the Canadian market is produced in both English and French and meets regulatory requirements

Clinical Evidence Requirements

Health Canada's Expectations

Health Canada's approach to clinical evidence is risk-proportionate. The expectations scale with device class and novelty:

Device Class	Clinical Evidence Expectation
Class I	Generally not required for licensing (no MDL needed)
Class II	Usually not required unless the device has novel clinical claims, a new indication for use, or involves a population for which safety data is limited
Class III	Clinical evidence often required, especially for implantable devices, devices with direct patient contact involving clinical risk, or devices with novel technological features
Class IV	Clinical evidence almost always required — clinical investigation data, substantial clinical literature, or both

Acceptable Forms of Clinical Evidence

Health Canada accepts multiple forms of clinical evidence:

Clinical investigation data — data from prospective clinical studies conducted under Good Clinical Practice (GCP / ISO 14155). This is the strongest form of evidence and is expected for Class IV devices with novel technology or indications.
Clinical literature — published clinical data from peer-reviewed literature demonstrating safety and effectiveness of the device or a substantially equivalent device. Systematic literature reviews are preferred over individual study citations.
Clinical experience data — post-market surveillance data, complaint data, and adverse event data from other markets where the device is already sold. This can supplement but rarely replace prospective clinical data for higher-risk devices.
Predicate/equivalent device data — clinical data generated for a substantially similar device already licensed in Canada or cleared/approved by a recognized regulatory authority (e.g., FDA, EU Notified Body). Health Canada may accept this if the devices are sufficiently similar and the data are relevant.

Clinical Investigation Requirements in Canada

If clinical investigation data is needed and the investigation will be conducted in Canada, the study must be conducted under the Medical Devices Regulations, Part 3 (Investigational Testing). Key requirements:

Investigational Testing Authorization (ITA) — an application to Health Canada is required before starting the investigation. The ITA must include the investigation plan, investigator information, informed consent documents, and ethics review board approval.
Research Ethics Board (REB) approval — all clinical investigations in Canada must be reviewed and approved by a Research Ethics Board (equivalent to an IRB in the US or an Ethics Committee in the EU).
Good Clinical Practice — investigations must comply with ICH GCP (E6) and ISO 14155.
Adverse event reporting — serious adverse events must be reported to Health Canada within prescribed timelines.

Practical tip: If you have existing clinical data from FDA-cleared or CE-marked devices, Health Canada will often accept this data as part of the MDL application — provided the device versions are the same and the data are relevant to the Canadian indication for use. This is one of the most significant advantages for manufacturers who have already obtained clearance/approval in the US or EU before entering Canada.

Recognition of Foreign Approvals

Does Health Canada Accept FDA or EU Approvals?

Health Canada is an independent regulatory authority and does not automatically recognize or accept foreign approvals. An FDA clearance or CE marking does not entitle you to a Canadian Medical Device License.

However, Health Canada does consider foreign regulatory status as part of its review:

Supporting evidence. FDA clearance letters, 510(k) summaries, EU certificates of conformity, and technical documentation prepared for other regulators can be included in the Canadian MDL application as supporting evidence.
Clinical data. Clinical data submitted to or accepted by the FDA or EU Notified Bodies is generally acceptable to Health Canada, provided it meets Canadian requirements for quality and relevance.
Testing data. Pre-clinical testing data (biocompatibility, electrical safety, performance testing) generated according to international standards (ISO, IEC) is accepted without the need to repeat testing.
Review efficiency. In practice, Health Canada reviewers are aware of device regulatory status in other jurisdictions. A device with FDA clearance and CE marking may receive a smoother review — not because Health Canada defers to those agencies, but because the available evidence base is typically more robust.

MDSAP as Cross-Jurisdictional Bridge

One of the most practical benefits of MDSAP for the Canadian market is that the same audit covers quality system requirements for multiple jurisdictions. If you already hold MDSAP certification for the US (FDA), adding Canada to the scope involves incremental audit effort — the Auditing Organization adds the Canadian regulatory requirements to the existing MDSAP audit.

The Interim Order Pathway

What Is the Interim Order Pathway?

During the COVID-19 pandemic, Health Canada introduced the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19. This pathway allowed expedited authorization of medical devices needed for the pandemic response — diagnostic tests, ventilators, PPE, and other devices — without the normal MDL process.

Current Status (2026)

The Interim Order pathway was a temporary emergency measure. As of 2026:

The original COVID-19 Interim Order has expired
Devices that were authorized under the Interim Order were required to transition to standard MDL licensing or cease sale
Health Canada has retained the legislative authority to issue future Interim Orders for public health emergencies, but no active Interim Orders for medical devices are currently in effect
The experience informed Health Canada's ongoing work to create more agile regulatory pathways for emergencies while maintaining safety standards

Lessons for the Regulatory Framework

The Interim Order experience demonstrated that Health Canada can review and authorize devices rapidly when necessary. It also highlighted gaps in the standard MDL process — particularly the need for more flexible pathways for innovative or urgently needed devices. Health Canada has been exploring regulatory modernization initiatives that build on this experience, including:

Expedited review pathways for devices addressing unmet clinical needs
Greater use of real-world evidence in regulatory decision-making
Alignment with international regulatory convergence initiatives under IMDRF

Special Access Programme (SAP)

When Standard Licensing Is Not an Option

The Special Access Programme allows healthcare professionals to request access to medical devices that are not licensed for sale in Canada, for use on a specific patient in an emergency situation or when conventional therapies have failed.

How the SAP Works

A Canadian healthcare professional identifies a clinical need that cannot be met by a device currently licensed in Canada
The healthcare professional submits a Special Access request to Health Canada, providing clinical justification, patient information, and device information
Health Canada reviews the request and, if approved, authorizes the importation and sale of the specific device for the specific patient
The manufacturer provides the device directly or through an intermediary
The authorization is patient-specific and time-limited — it does not constitute a device license and does not permit general sale

SAP vs. MDL

Feature	Special Access Programme	Medical Device License
Scope	Single patient, specific clinical situation	General commercial sale in Canada
Duration	Time-limited, patient-specific	Ongoing (with annual maintenance)
Application by	Healthcare professional	Manufacturer or authorized representative
MDSAP required?	No	Yes (Class II–IV)
Labeling requirements	Reduced (bilingual not always required)	Full bilingual labeling required
Typical use case	Compassionate use, emergency, no licensed alternative	Commercial market entry

Practical tip: Some manufacturers use the SAP strategically to build Canadian clinical experience with their device before pursuing full MDL licensing. If a small number of Canadian physicians are using your device through SAP, the clinical experience and user feedback can inform your MDL application. However, SAP is not a substitute for licensing and cannot be used for routine commercial distribution.

SAP Eligibility and Process Details

Healthcare professionals submitting SAP requests must be entitled under the laws of their province to provide health services. The programme considers requests for Class I through IV devices, including custom-made Class III and IV devices designed for a specific patient. Batch requests are also permitted for emergency stockpiling, where healthcare providers estimate one month's emergency requirements.

Key process details:

Priority processing: Devices required for life-threatening or emergency situations receive priority review. Standard applications typically receive responses within three business days.
Adverse event reporting: Healthcare professionals who obtain devices through SAP must report serious adverse events to both Health Canada and the device manufacturer within 72 hours.
Custom-made devices: The SAP covers custom-made devices designed for a specific patient, excluding glasses, orthotics, and items available through dispensers.
Batch authorizations: Healthcare facilities can request batches of unlicensed devices for emergency preparedness, not just individual patient use.

SAP in Practice: Real-World Examples

The SAP has played a significant role in bringing innovative technologies to Canadian patients before full licensing. Notable examples include:

Transcatheter Aortic Valve Implantation (TAVI): TAVI devices were first used in Canada through the SAP starting in 2005 for "compassionate clinical use" in patients who were not candidates for open-heart surgery. Use grew exponentially as clinical evidence accumulated, and TAVI eventually became a routine procedure and the devices received full MDLs. The SAP provided the bridge that allowed Canadian patients to access this life-saving technology years before formal licensing.

Silicone Gel Breast Implants: After silicone breast implants were withdrawn from the Canadian market due to safety concerns, they were accessible only through the SAP for years while additional safety studies were conducted. The SAP accounted for a substantial volume of requests — as of 2006, Health Canada had approved approximately 26,000 SAP requests for silicone implants. The devices were later re-licensed after the safety evidence was deemed sufficient.

Berlin Heart EXCOR Pediatric Cardiac Assist Device: This ventricular assist device for children with severe heart failure was accessed through the SAP before receiving full regulatory authorization, providing life-sustaining support for critically ill pediatric patients when no licensed alternative existed.

Custom Endovascular Stents: Patient-specific custom-made stents have been authorized through the SAP for patients whose anatomy does not accommodate standard commercially available devices.

SAP Volume and Trends

The SAP has seen dramatic growth over its history. In 2002, Health Canada received approximately 5,000 SAP requests — representing a 683% increase over the preceding four years. This volume created processing challenges, as the same staff handled both SAP requests and pre-market device evaluations. Cardiovascular devices have historically been the most common category, accounting for the majority of SAP authorizations in published studies examining the programme.

Fees and Timelines

MDL Application Fees

Health Canada charges fees for MDL applications and annual license maintenance under the Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124). Importantly, MDL application fees are not uniform across device classes — they are tiered by risk classification, and the differences are substantial.

MDL Application Fees (as of April 1, 2026)

Fee Type	Amount (CAD)
MDL application — Class II	$643
MDL application — Class III	$14,163
MDL application — Class III (near-patient IVD)	$30,169
MDL application — Class IV	$30,713
MDL amendment — Class II	$331
MDL amendment — Class III (manufacturing changes)	$4,470
MDL amendment — Class III (other significant changes)	$11,369
MDL amendment — Class IV (manufacturing changes)	$4,470
MDL amendment — Class IV (other significant changes)	$16,251
Private label application — Class II, III, or IV	$179
Annual right to sell fee — Class II, III, or IV	$452

MDEL Fees (as of April 1, 2026)

Fee Type	Amount (CAD)
MDEL application (new)	~$5,500 (adjusted annually by CPI)
MDEL annual licence review	Same as new application fee
MDEL reinstatement	Same as new application fee

Note: All fees are subject to annual CPI-based adjustment under section 4(1) of SOR/2019-124. The figures above reflect the fee schedule effective April 1, 2026. Always check the current Fees in Respect of Drugs and Medical Devices Order for the most up-to-date amounts.

Small Business Fee Remissions

Contrary to what many manufacturers assume, Health Canada does offer fee remissions for qualifying small businesses under SOR/2019-124:

Remission Type	Reduction	Eligibility
MDL application — small business	50% of the fee payable	Manufacturers meeting the regulatory definition of "small business" in their last completed fiscal year
MDL application — first-time small business	100% (full fee remitted)	Small businesses filing their first-ever MDL application, subject to conditions
MDEL application — small business	25% of the fee payable	Small businesses meeting eligibility criteria
Performance standard not met	25% of the fee payable	Any applicant, if Health Canada fails to meet its published service standard for the review

The regulations include anti-avoidance provisions: if it may reasonably be considered that one of the main reasons for the separate existence of two or more corporations is so that one of them meets the small business conditions, the corporations are deemed affiliated and the remission does not apply.

Practical tip: If you qualify as a small business, actively claim your fee remission. Many small manufacturers are unaware these remissions exist and pay full fees unnecessarily. Check the definition of "small business" in SOR/2019-124 carefully — it is based on gross revenue thresholds. For a first-time Class IV MDL application, the difference between full fee ($30,713) and 100% remission is significant.

Fee Comparison with Previous Years

Health Canada significantly restructured its medical device fees in recent years. The fee increases for Class III and IV devices have been substantial:

Fee Type	Pre-2019 (approximate)	April 2025	April 2026
Class II MDL application	~$400	$632	$643
Class III MDL application	~$400	$13,926	$14,163
Class IV MDL application	~$400	$30,199	$30,713
Annual right to sell	~$400	$452	$452

The shift from a flat fee structure (where all classes paid the same amount) to a risk-tiered fee structure represents a fundamental change in Health Canada's cost-recovery model. Class II applications remain relatively inexpensive, but Class III and IV application fees now represent a meaningful cost component of Canadian market entry.

Compared to the FDA — where a standard 510(k) user fee exceeds USD 26,000 and a PMA exceeds USD 579,000 — Health Canada's Class II fees remain remarkably low, but Class III and IV fees are now in a comparable range to FDA 510(k) fees. The real costs of Canadian market entry include not only the regulatory fees but also MDSAP certification costs, bilingual labeling, and the time invested in preparing the submission.

MDSAP Certification Costs

MDSAP certification is a significant cost that is separate from Health Canada's fees:

Cost Component	Typical Range (USD)
Initial MDSAP certification audit (Stage 1 + Stage 2)	$20,000–$50,000+
Annual surveillance audit	$10,000–$30,000+
Recertification audit (every 3 years)	$18,000–$45,000+

Costs vary widely depending on the number of countries in scope, the number of sites audited, the number of device types, and the Auditing Organization selected. Adding Canada to an existing MDSAP audit that already covers the US typically adds 1–2 audit days, translating to an incremental cost of $3,000–$8,000 per audit cycle.

Near-Patient IVD Devices: A Special Fee Category

Manufacturers of near-patient in vitro diagnostic (IVD) devices should be aware that Health Canada has a separate, higher fee category for Class III near-patient IVD applications: $30,169 CAD (as of April 2026), compared to $14,163 for standard Class III applications. Near-patient IVDs — devices designed for use at or near the site of patient care (point-of-care testing) — receive enhanced review scrutiny because incorrect results in decentralized testing settings can have immediate clinical consequences without the safety net of a full laboratory environment.

Review Timelines

Health Canada publishes target review timelines, but actual elapsed time from submission to license issuance depends on the completeness of the submission and the number of deficiency rounds.

Device Class	Health Canada Target Review Time	Typical Total Elapsed Time (Submission to License)
Class II	15–30 calendar days	1–3 months
Class III	60–75 calendar days	3–8 months
Class IV	75–90 calendar days	6–14 months

The target review times represent Health Canada's internal performance goals for the initial review cycle. They do not include time the applicant spends preparing deficiency responses. For Class III and IV devices, deficiency responses are common and can add weeks to months to the total timeline.

Health Canada Service Standards and Performance Data

Health Canada publishes formal service standards for medical device submission evaluations and reports on its performance against these targets. Understanding the published service standards helps manufacturers set realistic expectations.

Published Service Standards (Target Days to First Decision)

Submission Type	Target Days
Class II MDL — new application	15 calendar days
Class II MDL — amendment	15 calendar days
Class III MDL — new application	60 calendar days
Class III MDL — near-patient IVD application	60 calendar days
Class IV MDL — new application	75 calendar days
Class III MDL — manufacturing changes	60 calendar days
Class IV MDL — manufacturing changes	75 calendar days
Class III MDL — significant changes (non-manufacturing)	60 calendar days
Class IV MDL — significant changes (non-manufacturing)	75 calendar days
Class II, III, IV — private label applications	15 calendar days
Class II, III, IV — investigational testing authorization	30 calendar days
MDEL application	120 calendar days

Performance Against Targets

Health Canada's Medical Devices Directorate publishes annual performance reports and quarterly updates. Based on published data, Health Canada has historically achieved high compliance rates with its service standards:

In recent fiscal years, achievement rates have ranged from 90% to 100% across submission categories.
Cost-recovered submissions (MDL applications) have typically achieved 98–100% compliance with target timelines.
Non-cost-recovered submissions (such as investigational testing authorizations) have shown slightly lower but still strong compliance, typically around 90%.

The Medical Devices Directorate Performance Annual Report (published annually, covering April 1 through March 31) provides detailed breakdowns by submission type, including the number of applications received, the number of licences issued, the proportion of the workload exceeding target timelines, and the count of applications licensed after completion of scientific review. These reports are available by contacting Health Canada at publications@hc-sc.gc.ca or through the Health Canada website.

Practical tip: If Health Canada fails to meet its published service standard for your submission, you may be entitled to a 25% fee remission under SOR/2019-124. Track your submission dates carefully and compare against the applicable service standard. If the standard is not met, request the remission — Health Canada does not automatically apply it.

Practical tip: The single most effective way to minimize review time is to submit a complete, well-organized application with no gaps. Health Canada provides detailed guidance documents for each device class — follow them meticulously. A clean initial submission can clear review in close to the target timeline. A submission that triggers multiple deficiency rounds can take two to three times longer.

Post-Market Requirements

Mandatory Problem Reporting

Canada's post-market surveillance framework centers on Mandatory Problem Reporting — the requirement for manufacturers, importers, and distributors to report certain incidents to Health Canada.

A mandatory problem report is required when:

A medical device incident occurs that has led to the death or serious deterioration in the state of health of a patient, user, or other person
A medical device incident occurs that could lead to the death or serious deterioration in the state of health of a patient, user, or other person if the incident were to recur

Reporting Timelines

Incident Type	Reporting Timeline
Incident that led to death	Within 10 calendar days of becoming aware
Incident that led to serious deterioration in health	Within 10 calendar days of becoming aware
Incident that could lead to death or serious deterioration if it recurred	Within 30 calendar days of becoming aware

Reports are submitted through Health Canada's online mandatory problem reporting system. The report must include device identification, incident description, patient outcome (if known), and any actions taken.

Recalls

When a device presents a risk to health or does not meet regulatory requirements, the manufacturer (or importer/distributor) may need to initiate a recall. Health Canada classifies recalls by severity:

Recall Type	Risk Level	Description
Type I	Highest	Reasonable probability that the use of, or exposure to, the product will cause serious adverse health consequences or death
Type II	Moderate	Use of, or exposure to, the product may cause temporary adverse health consequences or where the probability of serious adverse health consequences is remote
Type III	Lowest	Use of, or exposure to, the product is not likely to cause adverse health consequences

Recall procedures must be documented and tested as part of your QMS. Health Canada monitors recalls through its Healthy Canadians recall database and can order a recall if the manufacturer does not act voluntarily.

Post-Market Surveillance Obligations

Beyond mandatory problem reporting, manufacturers are expected to:

Monitor device performance through complaint handling, trend analysis, and field feedback
Maintain and update risk management files as new post-market information becomes available
Report trends — if complaint data or adverse event data reveal a significant increase in incidents, this must be investigated and may require reporting to Health Canada
Cooperate with Health Canada inspections — Health Canada's Inspectorate can conduct post-market inspections of manufacturers, importers, and distributors to verify compliance with the Medical Devices Regulations

Canadian Representative Requirements

Do You Need a Canadian Representative?

Foreign manufacturers selling medical devices in Canada must have a Canadian presence for regulatory purposes. This is achieved through:

An MDEL holder in Canada — your Canadian importer or distributor holds the MDEL and acts as the point of contact for Health Canada. This is the most common arrangement for foreign manufacturers.
A Canadian authorized representative — if you are the MDL holder (manufacturer) and are located outside Canada, you must identify a Canadian contact person or entity that Health Canada can reach for regulatory matters.

What the Canadian Contact Must Do

The Canadian contact (whether the MDEL-holding importer/distributor or an authorized representative) must be able to:

Receive and respond to communications from Health Canada
Facilitate inspections and provide access to records
Support recall execution in Canada
Submit mandatory problem reports on behalf of the manufacturer (if the manufacturer does not do so directly)
Ensure bilingual labeling requirements are met for devices entering the Canadian market

Practical tip: Choosing the right Canadian partner is a strategic decision, not just a regulatory formality. Your Canadian importer/distributor is often the face of your company to Health Canada. They will handle adverse event reporting, recall coordination, and regulatory correspondence. Ensure they have the regulatory competence and infrastructure to meet these obligations.

Bilingual Labeling: English and French

The Requirement

Canada's Official Languages Act requires that medical device labeling be provided in both English and French. This requirement applies to:

Device labels (on the device itself and immediate packaging)
Instructions for use (IFU)
Outer packaging
Patient-facing information (patient guides, quick-start guides)

This is not optional. Health Canada will refuse an MDL application that includes only English-language labeling. It is one of the most common causes of screening deficiencies for foreign manufacturers entering the Canadian market for the first time.

What Must Be Bilingual

Labeling Element	Bilingual Required?
Device name on label	Yes
Intended use / indications for use	Yes
Warnings and precautions	Yes
Instructions for use	Yes
Storage conditions	Yes
Lot number / serial number identifier	Symbols acceptable (no translation needed if ISO 15223-1 symbols used)
Expiration date identifier	Symbols acceptable
Manufacturer name and address	As-is (no translation required)
UDI barcode	Not translated (encoded data)

Practical Approaches

Manufacturers typically handle bilingual labeling through one of these approaches:

Combined bilingual labels — a single label with both English and French text, separated clearly. This is the most common approach and works well when label space permits.
Separate English and French labels — two distinct labels applied to the device or packaging. This may be necessary when label space is limited.
Bilingual IFU booklet — instructions for use with English and French sections. A single booklet with both languages is acceptable; separate English and French booklets are also acceptable.
Multi-language labels — if your device is sold in multiple markets, you can include English and French alongside other languages (e.g., Spanish, German) as long as both official Canadian languages are present and legible.

Practical tip: Do not rely on machine translation for regulatory labeling. Medical device labeling must use precise terminology, and a mistranslation in a warning or instruction for use can have patient safety implications — and regulatory consequences. Use professional translators with medical device industry experience. Have the French translation reviewed by a native French-Canadian speaker (Canadian French differs from European French in certain technical and medical terminology).

Legal Basis for Bilingual Requirements

The bilingual requirement for medical devices arises from multiple overlapping legal frameworks:

The Medical Devices Regulations (SOR/98-282), Sections 21–23: These sections specify the information that must appear on device labels and in directions for use. Section 23 requires that the directions for use be provided in both English and French, or be "made available by the manufacturer as soon as possible at the request of the purchaser" in the other official language. In practice, Health Canada expects bilingual labeling to be included with the device at the time of sale, not provided only upon request.
The Consumer Packaging and Labelling Act: For devices sold to consumers (rather than exclusively to healthcare professionals), this Act requires bilingual labeling.
The Official Languages Act: Establishes English and French as the official languages of Canada and underpins the bilingual requirements across federal legislation.

Quebec: Additional French Language Requirements (Bill 96)

Manufacturers selling devices in Quebec must be aware of requirements that go beyond the federal bilingual standard. Quebec's Charter of the French Language, as amended by Bill 96 (An Act respecting French, the official and common language of Québec), imposes stricter French-language obligations:

French must be at least as prominent as English on all product labeling, warranty certificates, product manuals, and instructions for use sold in Quebec. Equal presentation is the minimum; French may be more prominent, but English may not be more prominent than French.
Public signage and written advertising in Quebec must be predominantly in French.
Contracts and communications — Quebec law may require that certain commercial communications and standard-form contracts with Quebec customers be available in French.
Penalties for non-compliance with Quebec language laws can include fines and orders to remove non-compliant products from sale.

The practical implication is that manufacturers often need to produce Quebec-specific packaging or labeling that gives equal or greater prominence to French text, in addition to meeting the federal bilingual requirements. Some manufacturers produce separate labeling for Quebec distribution, while others design all Canadian labeling to meet Quebec's stricter standards.

Use of ISO 15223-1 Symbols

Health Canada accepts the use of internationally recognized symbols from ISO 15223-1 (Symbols to be used with information to be supplied by the manufacturer of medical devices) on device labels. Where a recognized symbol conveys the required information (such as lot number, expiration date, manufacturer, sterilization method, or single-use indicators), no translation is needed. This can significantly reduce the labeling burden for fields that would otherwise require bilingual text.

Commonly used symbols that avoid the need for bilingual translation include:

Symbol Meaning	ISO 15223-1 Reference
Manufacturer	ISO 15223-1, symbol 5.1.1
Date of manufacture	ISO 15223-1, symbol 5.1.3
Use-by date (expiration)	ISO 15223-1, symbol 5.1.4
Lot number (batch code)	ISO 15223-1, symbol 5.1.5
Serial number	ISO 15223-1, symbol 5.1.6
Single use (do not reuse)	ISO 15223-1, symbol 5.4.2
Sterilized using [method]	ISO 15223-1, symbol 5.2.x
Caution / Consult IFU	ISO 15223-1, symbol 5.4.4
Keep dry	ISO 15223-1, symbol 5.3.4
Temperature limitation	ISO 15223-1, symbol 5.3.7

Practical tip: Maximizing the use of ISO 15223-1 symbols on your labels reduces the amount of text that must be translated and formatted bilingually. This is especially valuable when label space is limited. However, warnings, contraindications, and directions for use cannot be replaced by symbols alone — these must be in both English and French text.

Recent Regulatory Changes (2024–2026)

Regulatory Modernization Initiatives

Health Canada has been actively modernizing its medical device regulatory framework. Key developments from 2024 through early 2026 include:

1. Agile Licensing Framework

Health Canada has been developing an agile regulatory framework intended to provide more flexible and proportionate pathways for device authorization. This includes:

Streamlined review pathways for devices with strong pre-existing evidence from recognized regulatory authorities
Enhanced use of real-world evidence (RWE) to support regulatory decisions, particularly for post-market modifications and expanded indications
Pilot programs for continuous evidence generation and iterative licensing

The Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing) were published in Canada Gazette, Part II on November 29, 2024, and are now law. They are being implemented on a staggered basis:

Implementation Date	What Takes Effect
December 18, 2024	Provisions related to public health emergency drugs (already in effect)
January 1, 2026	Terms and Conditions (T&Cs) authority for Class II, III, and IV medical devices
April 1, 2027	Remaining provisions, replacing the Notice of Compliance with Conditions policy

Terms and Conditions (T&Cs) for Medical Devices: The most significant change for device manufacturers is Health Canada's expanded authority to impose terms and conditions on MDLs. Previously limited to testing-related conditions, Health Canada can now impose T&Cs on any Class II, III, or IV medical device licence. T&Cs may require manufacturers to:

Conduct additional post-market studies or surveillance activities
Submit additional safety or performance data after the device reaches market
Implement specific risk management measures
Provide disaggregated clinical trial data (by sex, race, ethnicity)
Meet enhanced quality assurance requirements during transportation and storage

When deciding whether to impose T&Cs, Health Canada must consider "whether there are less burdensome ways for those objectives to be met." T&Cs can be imposed, modified, or removed at any time during a device's lifecycle. This represents a shift from a binary approve/reject model to a more flexible approach where Health Canada can grant market access while requiring ongoing evidence generation.

Foreign regulator reliance: The framework also enables Health Canada to rely on decisions from trusted international regulators in certain circumstances, potentially accelerating market access for devices already approved in recognized jurisdictions.

Practical tip: Manufacturers should prepare for T&Cs to become a routine part of the MDL process for higher-risk devices. Build the capability to conduct post-market studies, collect real-world data, and respond to Health Canada information requests into your post-market surveillance infrastructure. Devices that might previously have faced a simple approve/reject decision may now receive conditional approval with ongoing obligations.

2. SaMD Regulatory Approach

Health Canada has been refining its regulatory approach to Software as a Medical Device (SaMD), aligning with the IMDRF SaMD framework:

Published updated guidance on the classification of SaMD using the IMDRF risk categorization framework
Increasing focus on cybersecurity requirements for connected medical devices
Engagement with international partners on the regulation of AI/ML-enabled medical devices, including pre-determined change control plans

3. MDSAP Program Evolution

The MDSAP program continues to evolve:

Expanded audit requirements covering cybersecurity and software validation
Increased focus on supply chain integrity and supplier management in audit scope
Ongoing improvements to the MDSAP IT systems used for certificate management
Discussions at the IMDRF level about potential expansion of MDSAP to additional countries

4. Post-Market Surveillance Strengthening

Health Canada has enhanced post-market surveillance activities:

Increased use of signal detection and data analytics to identify emerging device safety issues
Enhanced mandatory problem reporting requirements, including electronic reporting capabilities
Greater international collaboration on device safety signals through IMDRF

5. Updated MDL Guidance (February 2026)

On November 21, 2025, Health Canada published a new version of its Guidance on Managing Applications for Medical Device Licences, effective February 2, 2026. This guidance replaces the 2020 version and applies to all MDL applications and reconsideration requests in progress on or after the effective date. Key changes include:

Mandatory electronic submission through the Regulatory Enrolment Process (REP) and Common Electronic Submissions Gateway (CESG) — email submissions are no longer accepted for Class II, III, and IV device submissions and amendments
IMDRF Table of Contents structure — all submissions must follow Health Canada's standardized IMDRF ToC, including specific foldering and naming conventions. Non-compliant submissions may be refused at administrative screening.
Revised screening procedures — Health Canada now issues a request for outstanding information with a 10-day response deadline for administrative deficiencies. Failure to respond leads to rejection without fee charges.
Updated communication protocols for deficiency notices and reconsideration requests
Broader scope covering Class II, III, and IV new applications, minor change applications, private label submissions, unsolicited information submissions, and withdrawal requests

Manufacturers with submissions in progress should update their workflows to ensure CESG/REP compliance, as the guidance applies retroactively to in-progress applications from the effective date.

6. Medical Device Fee Restructuring

Health Canada has implemented a fundamental restructuring of its medical device fee model. Prior to 2019, MDL application fees were a flat rate (approximately CAD $400) regardless of device class. Under the current Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124), fees are now tiered by device class and risk level. As of April 2026, Class IV MDL application fees exceed CAD $30,000 — a nearly 80-fold increase from the flat fee era. Fees are adjusted annually by the Consumer Price Index. The fee restructuring reflects Health Canada's cost-recovery objectives and the significantly different levels of review effort required across device classes.

7. Right to Repair Considerations

Health Canada, in alignment with broader government policy, has been examining the implications of right-to-repair legislation for medical devices — balancing patient safety requirements with the economic and environmental benefits of device repairability. This is an ongoing policy discussion that may affect future regulatory requirements.

Canada vs. FDA vs. EU: A Comparative Overview

Understanding how the Canadian regulatory system compares to the US and EU frameworks helps manufacturers plan multi-market strategies efficiently.

Aspect	Canada (Health Canada)	US (FDA)	EU (MDR/IVDR)
Governing legislation	Food and Drugs Act + Medical Devices Regulations	FD&C Act + 21 CFR Parts 800–1299	Regulation (EU) 2017/745 (MDR) + 2017/746 (IVDR)
Classification system	4 classes (I–IV)	3 classes (I–III)	4 classes (I, IIa, IIb, III for MDR; A–D for IVDR)
Pre-market authorization	MDL (Class II–IV); Class I exempt	510(k), De Novo, PMA, HDE	CE marking via self-declaration (Class I) or Notified Body
QMS standard	ISO 13485 (via MDSAP)	QMSR (21 CFR 820, aligned with ISO 13485)	ISO 13485 (via Notified Body audit)
QMS audit mechanism	MDSAP (mandatory)	FDA inspection + MDSAP (voluntary)	Notified Body audit
Clinical evidence	Risk-proportionate; accepts foreign data	Risk-proportionate; typically requires US-relevant data	Clinical evaluation mandatory for all classes; PMCF for implants and Class III
Labeling language	Bilingual (English + French)	English	Language of member state where sold
UDI requirement	Required (aligned with IMDRF)	Required (FDA UDI system)	Required (EU UDI system)
Post-market reporting	Mandatory problem reports (10/30 days)	MDR/MedWatch (5/30 days for manufacturers)	Serious incident reporting (15 days, or 10 days for life-threatening)
Application fees	Risk-tiered (CAD $643 Class II; $14,163 Class III; $30,713 Class IV)	High (USD $26K+ for 510(k); $579K+ for PMA)	Notified Body fees (vary widely; EUR $10K–$100K+)
Typical review time	1–14 months depending on class	3–12+ months depending on pathway	6–18+ months (Notified Body review + Competent Authority)
Foreign manufacturer access	Through Canadian importer/distributor (MDEL holder)	Through US Agent + establishment registration	Through Authorized Representative in the EU
Emergency pathway	Interim Order (when active); Special Access Programme	EUA (Emergency Use Authorization)	Article 59 derogation (by member state)

Key Differences That Catch Manufacturers Off Guard

MDSAP is mandatory in Canada but voluntary in the US. Many US manufacturers who have never been through an MDSAP audit are surprised to discover they must obtain MDSAP certification before they can apply for a Canadian MDL. This single requirement adds 6–12 months and $20,000–$50,000 to the timeline before the MDL application is even submitted.
Canada has four device classes; the US has three. A device that is Class II (510(k)) in the US may be Class III or even Class IV in Canada. This means a device with a relatively straightforward 510(k) pathway in the US may face a much more demanding review in Canada.
Bilingual labeling is non-negotiable. In the US, English-only labeling is standard. In Canada, every word on the label, IFU, and packaging must be in both English and French. This requirement has real cost and timeline implications — professional translation, label redesign, regulatory review of translated text.
Health Canada's fees are now risk-tiered and no longer negligible for higher-class devices. While the Class II MDL application fee of CAD $643 remains modest, Class III applications now cost $14,163 and Class IV applications cost $30,713. When you add MDSAP certification ($20K–$50K), bilingual labeling ($5K–$20K for translation and redesign), Canadian distributor setup, and regulatory consulting, the total cost of Canadian market entry for a Class III or IV device can reach $75K–$200K. However, qualifying small businesses can receive 50–100% fee remissions.
Review timelines are generally shorter than the EU but can match the FDA. For Class II devices, Canada is fast. For Class IV devices, the total elapsed time (including deficiency rounds) can rival FDA PMA timelines.

Tips for Foreign Manufacturers Entering Canada

Strategic Planning

Start with MDSAP. If you do not already have MDSAP certification, this is your longest lead-time item. Begin the MDSAP process 12–18 months before your target Canadian launch date. If you already have MDSAP for other markets, adding Canada to scope is much faster.
Classify early. Do not assume your Canadian classification matches your US or EU classification. Review the Canadian classification rules independently and, if uncertain, request a classification determination from Health Canada.
Choose your Canadian partner carefully. Your importer/distributor will hold the MDEL, handle adverse event reporting, manage recalls, and serve as your interface with Health Canada. Regulatory competence matters as much as commercial capability.
Invest in bilingual labeling from the start. If you are designing labeling for a new device, plan for bilingual English/French from the beginning. Retrofitting bilingual text onto labels designed for English-only markets is more expensive and time-consuming than designing for bilingual from day one.
Leverage existing regulatory data. If you have an FDA clearance or CE marking, your technical file likely contains most of the evidence Health Canada needs. Organize and cross-reference it to the Canadian requirements rather than starting from scratch.

Common Pitfalls

Submitting without MDSAP. The application will be refused. There are no exceptions for Class II–IV devices.
English-only labeling. The application will be refused or receive a deficiency letter. There are no exceptions.
Assuming FDA clearance transfers to Canada. It does not. You must submit a separate MDL application and go through Health Canada's review process. FDA clearance can support the application but does not replace it.
Underestimating Class III/IV review rigor. Some manufacturers, accustomed to the FDA 510(k) process, are surprised by the depth of Health Canada's review for Canadian Class III devices. Prepare accordingly.
Neglecting post-market obligations. Obtaining the MDL is not the end — it is the beginning. Mandatory problem reporting, recall readiness, annual license maintenance, and MDSAP certificate renewal are ongoing obligations. Failure to meet any of these can result in license suspension.
Letting the MDSAP certificate lapse. If your MDSAP certificate expires, your MDLs are at risk. Track your audit schedule and renewal dates carefully.
Using European French for Canadian labeling. Canadian French (Quebecois French) uses some different terminology than European French, particularly for technical and medical terms. Use translators familiar with Canadian French regulatory language.

Recommended Timeline for Market Entry

For a Class III device from a manufacturer with no existing MDSAP certification:

Milestone	Timeline	Cumulative
Classify device for Canada	Month 0–1	1 month
Select MDSAP Auditing Organization	Month 1–2	2 months
Prepare QMS for MDSAP audit (gap analysis, remediation)	Month 2–6	6 months
MDSAP Stage 1 audit	Month 6–7	7 months
Address Stage 1 findings; prepare for Stage 2	Month 7–8	8 months
MDSAP Stage 2 audit	Month 8–10	10 months
Receive MDSAP certificate	Month 10–12	12 months
Prepare bilingual labeling	Month 6–10 (parallel)	—
Compile MDL application	Month 10–12 (parallel with MDSAP completion)	—
Submit MDL application	Month 12	12 months
Health Canada review + deficiency responses	Month 12–18	18 months
MDL issued	Month 18	~18 months total

For a manufacturer that already holds MDSAP certification (without Canada in scope), the timeline compresses to approximately 8–12 months by eliminating the full MDSAP process and replacing it with a scope extension at the next audit cycle.

For Class II devices, the total timeline is shorter — typically 6–12 months — because the review is faster and less likely to involve deficiency rounds.

Frequently Asked Questions

Can I sell Class I devices in Canada without any license? You do not need an MDL for Class I devices, but you (or your Canadian importer/distributor) still need an MDEL. You must also comply with labeling requirements, including bilingual English/French labeling. Class I devices are not exempt from regulation — they are simply exempt from the MDL requirement.

Is MDSAP required for Class I devices? No. MDSAP certification is required only for Class II, III, and IV device licenses. However, if you manufacture Class I and Class II+ devices, you will likely already have MDSAP for your Class II+ products.

Can I reference my FDA 510(k) clearance in the Canadian MDL application? Yes, and you should. Include the 510(k) clearance letter, summary, and relevant performance data. Health Canada does not accept FDA clearance as a substitute for its own review, but FDA-cleared evidence is accepted as supporting documentation.

How long does an MDL remain valid? MDLs remain valid as long as you pay the annual license review fee and maintain compliance with all regulatory requirements, including holding a valid MDSAP certificate. There is no fixed expiration date — but the license can be suspended or cancelled if you fail to meet ongoing obligations.

Can I apply for an MDL while my MDSAP audit is in progress? No. You must have a valid MDSAP certificate in hand before submitting the MDL application. Health Canada will not accept an application without a current MDSAP certificate.

What if Health Canada reclassifies my device? If regulatory changes or new guidance result in your device being reclassified to a higher class, you will need to submit a new MDL application (or amend your existing one) to reflect the new classification. You may also need to provide additional evidence appropriate for the higher class.

Are there any small business fee reductions? Yes. Under the Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124), qualifying small businesses can receive a 50% fee remission on MDL application fees, and first-time small business applicants may receive a 100% fee remission (full fee waived) on their first MDL application. Small businesses also receive a 25% reduction on MDEL fees. These remissions are significant — for a first-time Class IV MDL application, the remission saves over $30,000 CAD. Check the definition of "small business" in SOR/2019-124 to determine eligibility, as it is based on gross revenue thresholds.

Key Takeaways

Two licenses are required for Class II–IV devices: the MDEL (company license) and the MDL (product license). Class I devices need only the MDEL.
MDSAP is mandatory. No MDSAP certificate with Canada in scope means no MDL for Class II–IV devices. This has been the case since January 1, 2019.
Classification drives everything. Canadian classification does not always align with US or EU classification. Classify independently and early.
Bilingual labeling is non-negotiable. All labeling must be in English and French. Use professional Canadian French translators.
Health Canada fees are now risk-tiered. Class II fees remain low ($643), but Class III ($14,163) and Class IV ($30,713) fees are now significant. Small business remissions of 50–100% are available. MDSAP certification and bilingual labeling remain major cost drivers beyond the regulatory fees.
Foreign approvals help but do not replace the Canadian process. FDA and EU data can support the MDL application, but Health Canada conducts its own independent review.
Post-market obligations are serious. Mandatory problem reporting, recall capability, and MDSAP certificate maintenance are ongoing requirements that directly affect your ability to maintain market access.
Plan 12–18 months for first-time market entry (Class III/IV with no existing MDSAP). With existing MDSAP, the timeline compresses significantly.

Canada is a well-regulated, transparent, and accessible market for medical device manufacturers who invest the time to understand the requirements. The regulatory framework is rigorous but predictable. Manufacturers who approach it with thorough preparation — proper classification, early MDSAP certification, complete bilingual labeling, and a strong Canadian partner — find that Health Canada is a straightforward regulator to work with.